Annual report pursuant to Section 13 and 15(d)

Organization and Principal Activities - Additional Information (Details)

v3.24.1
Organization and Principal Activities - Additional Information (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
Segment
shares
Dec. 31, 2022
USD ($)
Organization Consolidation And Presentation Of Financial Statements [Line Items]    
Date of incorporation Apr. 21, 2003  
Number of operating segments | Segment 1  
Accumulated deficit $ 559,408 $ 452,615
Net proceeds from issuance of common stock 11,971 $ 56,270
Unrestricted cash, cash equivalents and marketable securities $ 333,700  
Substantial doubt about going concern, within one year false  
Headquartered in South San Francisco  
Headquartered in state CA  
Vaxcyte, Inc. ('Vaxcyte")    
Organization Consolidation And Presentation Of Financial Statements [Line Items]    
Unrestricted cash cash equivalents and equity securities at carrying value $ 41,900  
Minimum    
Organization Consolidation And Presentation Of Financial Statements [Line Items]    
Period from issuance date of unaudited interim condensed financial statements 12 months  
Common Stock | At-the-Market (“ATM")    
Organization Consolidation And Presentation Of Financial Statements [Line Items]    
Shares of common stock | shares 1,857,410  
Gross proceeds from issuance of common stock $ 12,400  
Underwriting discounts and commissions and other offering expenses 400  
Net proceeds from issuance of common stock $ 12,000